IPIX Stock Overview
A clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Innovation Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0002 |
| 52 Week High | US$0.019 |
| 52 Week Low | US$0.000001 |
| Beta | 0.23 |
| 11 Month Change | -60.00% |
| 3 Month Change | -33.33% |
| 1 Year Change | -96.40% |
| 33 Year Change | -99.69% |
| 5 Year Change | -99.73% |
| Change since IPO | -99.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| IPIX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 100.0% | 2.4% | 2.2% |
| 1Y | -96.4% | 16.2% | 31.7% |
Return vs Industry: IPIX underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: IPIX underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| IPIX volatility | |
|---|---|
| IPIX Average Weekly Movement | 112.9% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IPIX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IPIX's weekly volatility has decreased from 160% to 113% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 4 | Leo Ehrlich | www.ipharminc.com |
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017.
Innovation Pharmaceuticals Inc. Fundamentals Summary
| IPIX fundamental statistics | |
|---|---|
| Market cap | US$105.75k |
| Earnings (TTM) | -US$2.62m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs IPIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPIX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$2.62m |
| Earnings | -US$2.62m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.005 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 59.8% |
How did IPIX perform over the long term?
See historical performance and comparison